Charles Dadswell Sells 1,609 Shares of Illumina, Inc. (ILMN) Stock

Illumina, Inc. (NASDAQ:ILMN) SVP Charles Dadswell sold 1,609 shares of the company’s stock in a transaction dated Friday, November 3rd. The stock was sold at an average price of $207.88, for a total transaction of $334,478.92. Following the sale, the senior vice president now directly owns 7,217 shares in the company, valued at $1,500,269.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Charles Dadswell also recently made the following trade(s):

  • On Tuesday, October 3rd, Charles Dadswell sold 145 shares of Illumina stock. The stock was sold at an average price of $202.23, for a total transaction of $29,323.35.
  • On Tuesday, September 5th, Charles Dadswell sold 145 shares of Illumina stock. The stock was sold at an average price of $205.71, for a total transaction of $29,827.95.

Shares of Illumina, Inc. (NASDAQ ILMN) opened at $211.20 on Thursday. The company has a quick ratio of 3.73, a current ratio of 4.22 and a debt-to-equity ratio of 0.41. The firm has a market cap of $30,914.04, a price-to-earnings ratio of 61.91, a price-to-earnings-growth ratio of 3.50 and a beta of 0.74. Illumina, Inc. has a twelve month low of $119.37 and a twelve month high of $214.50.

Illumina (NASDAQ:ILMN) last posted its earnings results on Tuesday, October 24th. The life sciences company reported $1.11 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.99 by $0.12. Illumina had a net margin of 30.34% and a return on equity of 19.42%. The company had revenue of $714.00 million for the quarter, compared to analyst estimates of $692.77 million. During the same period last year, the business posted $0.97 earnings per share. The business’s revenue for the quarter was up 17.6% compared to the same quarter last year. sell-side analysts anticipate that Illumina, Inc. will post 3.75 EPS for the current year.

TRADEMARK VIOLATION WARNING: This piece was first reported by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this piece on another site, it was illegally copied and reposted in violation of international copyright & trademark legislation. The correct version of this piece can be viewed at https://sportsperspectives.com/2017/11/09/charles-dadswell-sells-1609-shares-of-illumina-inc-ilmn-stock.html.

Several analysts have recently commented on the stock. BidaskClub cut shares of Illumina from a “hold” rating to a “sell” rating in a research note on Thursday, August 17th. Zacks Investment Research cut shares of Illumina from a “buy” rating to a “hold” rating in a research note on Friday, August 4th. J P Morgan Chase & Co reissued an “overweight” rating and set a $250.00 price target on shares of Illumina in a research note on Wednesday, August 2nd. Canaccord Genuity reissued a “buy” rating and set a $230.00 price target (up from $215.00) on shares of Illumina in a research note on Thursday, October 12th. Finally, Goldman Sachs Group, Inc. (The) reissued a “neutral” rating and set a $200.00 price target on shares of Illumina in a research note on Tuesday, September 26th. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and thirteen have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $200.88.

Large investors have recently modified their holdings of the stock. Paradigm Asset Management Co. LLC raised its holdings in shares of Illumina by 5.6% during the second quarter. Paradigm Asset Management Co. LLC now owns 950 shares of the life sciences company’s stock worth $165,000 after acquiring an additional 50 shares during the period. Patriot Financial Group Insurance Agency LLC raised its holdings in shares of Illumina by 1.4% during the second quarter. Patriot Financial Group Insurance Agency LLC now owns 3,126 shares of the life sciences company’s stock worth $528,000 after acquiring an additional 43 shares during the period. Cambridge Investment Research Advisors Inc. raised its holdings in shares of Illumina by 298.7% during the second quarter. Cambridge Investment Research Advisors Inc. now owns 10,447 shares of the life sciences company’s stock worth $1,813,000 after acquiring an additional 7,827 shares during the period. Eagle Asset Management Inc. acquired a new stake in shares of Illumina during the second quarter worth $27,175,000. Finally, Stephens Investment Management Group LLC raised its holdings in shares of Illumina by 0.5% during the second quarter. Stephens Investment Management Group LLC now owns 168,706 shares of the life sciences company’s stock worth $29,274,000 after acquiring an additional 803 shares during the period. Institutional investors and hedge funds own 93.07% of the company’s stock.

About Illumina

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Insider Buying and Selling by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply